B Mullhaupt
Effect of hepatitis B virus on steatosis in hepatitis C virus co-infected subjects: A multi-centre study and systematic review
Goossens N, Semmo N, Mullhaupt B, Semela D, Malinverni R, Moradpour D, Heim M, Trincucci G, Rubbia-Brandt L, Negro F, Wedemeyer H, Adinolfi L, de Vito C, Mangia A, Clément S, Cenderello G, Barrera F, D'Ambrosio R, Coppola N, Zampino R, Stanzione M, BOSTIC Study Group. Effect of hepatitis B virus on steatosis in hepatitis C virus co-infected subjects: A multi-centre study and systematic review. J Viral Hepat 2018; 25:920-929.
17.04.2018Effect of hepatitis B virus on steatosis in hepatitis C virus co-infected subjects: A multi-centre study and systematic review
17.04.2018J Viral Hepat 2018; 25:920-929
Goossens N, Semmo N, Mullhaupt B, Semela David, Malinverni R, Moradpour D, Heim M, Trincucci G, Rubbia-Brandt L, Negro F, Wedemeyer H, Adinolfi L E, de Vito C, Mangia A, Clément S, Cenderello G, Barrera F, D'Ambrosio R, Coppola N, Zampino R, Stanzione M, BOSTIC Study Group
Trends in hepatitis C-related mortality in Switzerland
Keiser O, Spoerri A, Negro F, Estill J, Bertisch B, Brezzi M, Semela D, Terziroli B, Bruggmann P, Moradpour D, Dufour J, Junker C, Mullhaupt B, Giudici F, Swiss Hepatitis C Cohort Study and the Swiss National Cohort. Trends in hepatitis C-related mortality in Switzerland. J Viral Hepat 2017; 25:152-160.
20.11.2017Trends in hepatitis C-related mortality in Switzerland
20.11.2017J Viral Hepat 2017; 25:152-160
Keiser O, Spoerri A, Negro F, Estill J, Bertisch B, Brezzi M, Semela David, Terziroli B, Bruggmann P, Moradpour D, Dufour J-F, Junker C, Mullhaupt B, Giudici F, Swiss Hepatitis C Cohort Study and the Swiss National Cohort
Impact of common risk factors of fibrosis progression in chronic hepatitis C
Rüeger S, Halfon P, Bourlière M, Talal A, Jacobson I, Patin E, Nalpas B, Poynard T, Pol S, Abel L, Kutalik Z, Argiro L, George J, Bochud P, Dufour J, Mullhaupt B, Semela D, Heim M, Moradpour D, Cerny A, Malinverni R, Booth D, Suppiah V, Negro F. Impact of common risk factors of fibrosis progression in chronic hepatitis C. Gut 2014
11.09.2014Impact of common risk factors of fibrosis progression in chronic hepatitis C
11.09.2014Gut 2014
Rüeger S, Halfon P, Bourlière M, Talal A H, Jacobson I M, Patin E, Nalpas B, Poynard T, Pol S, Abel L, Kutalik Z, Argiro L, George J, Bochud P-Y, Dufour J-F, Mullhaupt B, Semela David, Heim M H, Moradpour D, Cerny A, Malinverni R, Booth D R, Suppiah V, Negro F
Strategies to manage hepatitis C virus (HCV) disease burden
Kautz A, Myers R, Nemecek V, Øvrehus A, Parkes J, Peltekian K, Ramji A, Razavi H, Reis N, Roberts S, Mullhaupt B, Moreno C, Mendes Correa M, Kaymakoglu S, Krajden M, Krarup H, Laleman W, Lavanchy D, Lázaro P, Marinho R, Marotta P, Mauss S, Roudot-Thoraval F, Ryder S, Vandijck D, Vogel W, Waked I, Weis N, Wiegand J, Yosry A, Zekry A, Negro F, Sievert W, van Thiel I, Van Damme P, Urbanek P, Sarmento-Castro R, Sarrazin C, Semela D, Sherman M, Shiha G, Sperl J, Stärkel P, Stauber R, Thompson A, Gower E, Kaita K, Wedemeyer H, Bihl F, Bilodeau M, Blasco A, Brandão Mello C, Bruggmann P, Calinas F, Calleja J, Cheinquer H, Christensen P, Berg T, Balık I, Aleman S, Duberg A, Buti M, Rosenberg W, Frankova S, Esmat G, Örmeci N, Van Vlierberghe H, Gschwantler M, Akarca U, Clausen M, Coelho H, Gerstoft J, Giria J, Gonçales F, Guimarães Pessôa M, Hézode C, Hindman S, Hofer H, Husa P, Idilman R, García-Samaniego J, Ferreira P, Ferraz M, Cornberg M, Cramp M, Dore G, Doss W, El-Sayed M, Ergör G, Estes C, Falconer K, Félix J, Kåberg M. Strategies to manage hepatitis C virus (HCV) disease burden. J Viral Hepat 2014; 21 Suppl 1:60-89.
01.05.2014Strategies to manage hepatitis C virus (HCV) disease burden
01.05.2014J Viral Hepat 2014; 21 Suppl 1:60-89
Kautz A, Myers R P, Nemecek V, Øvrehus A L H, Parkes J, Peltekian K M, Ramji A, Razavi H, Reis N, Roberts S K, Mullhaupt B, Moreno C, Mendes Correa M C, Kaymakoglu S, Krajden M, Krarup H, Laleman W, Lavanchy D, Lázaro P, Marinho R T, Marotta P, Mauss S, Roudot-Thoraval F, Ryder S D, Vandijck D, Vogel W, Waked I, Weis N, Wiegand J, Yosry A, Zekry A, Negro F, Sievert W, van Thiel I, Van Damme P, Urbanek P, Sarmento-Castro R, Sarrazin C, Semela David, Sherman M, Shiha G E, Sperl J, Stärkel P, Stauber R E, Thompson A J, Gower E, Kaita K D E, Wedemeyer H, Bihl F, Bilodeau M, Blasco A J, Brandão Mello C E, Bruggmann P, Calinas F, Calleja J L, Cheinquer H, Christensen P B, Berg T, Balık I, Aleman S, Duberg A S, Buti M, Rosenberg W M, Frankova S, Esmat G, Örmeci N, Van Vlierberghe H, Gschwantler M, Akarca U, Clausen M, Coelho H S M, Gerstoft J, Giria J A, Gonçales F L, Guimarães Pessôa M, Hézode C, Hindman S J, Hofer H, Husa P, Idilman R, García-Samaniego J, Ferreira P R, Ferraz M L G, Cornberg M, Cramp M E, Dore G J, Doss W, El-Sayed M H, Ergör G, Estes C, Falconer K, Félix J, Kåberg M
The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm
Kaita K, Nemecek V, Örmeci N, Øvrehus A, Parkes J, Pasini K, Peltekian K, Ramji A, Reis N, Roberts S, Negro F, Murphy K, Moreno C, Kautz A, Kaymakoglu S, Krajden M, Krarup H, Laleman W, Lavanchy D, Marinho R, Marotta P, Mauss S, Rosenberg W, Roudot-Thoraval F, Ryder S, Van Vlierberghe H, Vandijck D, Wedemeyer H, Weis N, Wiegand J, Yosry A, Zekry A, Cornberg M, Mullhaupt B, van Thiel I, Van Damme P, Urbanek P, Sarmento-Castro R, Semela D, Sherman M, Shiha G, Sievert W, Sperl J, Stärkel P, Stauber R, Thompson A, Estes C, Kåberg M, Razavi H, Berg T, Bihl F, Bilodeau M, Blasco A, Brandão Mello C, Bruggmann P, Buti M, Calleja J, Cheinquer H, Balık I, Aleman S, Akarca U, Waked I, Sarrazin C, Myers R, Idilman R, Calinas F, Vogel W, Mendes Correa M, Hézode C, Lázaro P, Christensen P, Clausen M, Coelho H, García-Samaniego J, Gerstoft J, Giria J, Gonçales F, Gower E, Gschwantler M, Guimarães Pessôa M, Hindman S, Hofer H, Frankova S, Ferreira P, Ferraz M, Cramp M, Dore G, Doss W, Duberg A, El-Sayed M, Ergör G, Esmat G, Falconer K, Félix J, Husa P. The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm. J Viral Hepat 2014; 21 Suppl 1:34-59.
01.05.2014The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm
01.05.2014J Viral Hepat 2014; 21 Suppl 1:34-59
Kaita K D E, Nemecek V, Örmeci N, Øvrehus A L H, Parkes J, Pasini K, Peltekian K M, Ramji A, Reis N, Roberts S K, Negro F, Murphy K, Moreno C, Kautz A, Kaymakoglu S, Krajden M, Krarup H, Laleman W, Lavanchy D, Marinho R T, Marotta P, Mauss S, Rosenberg W M, Roudot-Thoraval F, Ryder S D, Van Vlierberghe H, Vandijck D, Wedemeyer H, Weis N, Wiegand J, Yosry A, Zekry A, Cornberg M, Mullhaupt B, van Thiel I, Van Damme P, Urbanek P, Sarmento-Castro R, Semela David, Sherman M, Shiha G E, Sievert W, Sperl J, Stärkel P, Stauber R E, Thompson A J, Estes C, Kåberg M, Razavi H, Berg T, Bihl F, Bilodeau M, Blasco A J, Brandão Mello C E, Bruggmann P, Buti M, Calleja J L, Cheinquer H, Balık I, Aleman S, Akarca U, Waked I, Sarrazin C, Myers R P, Idilman R, Calinas F, Vogel W, Mendes Correa M C, Hézode C, Lázaro P, Christensen P B, Clausen M, Coelho H S M, García-Samaniego J, Gerstoft J, Giria J A, Gonçales F L, Gower E, Gschwantler M, Guimarães Pessôa M, Hindman S J, Hofer H, Frankova S, Ferreira P R, Ferraz M L G, Cramp M E, Dore G J, Doss W, Duberg A S, El-Sayed M H, Ergör G, Esmat G, Falconer K, Félix J, Husa P
Historical epidemiology of hepatitis C virus (HCV) in selected countries
Kåberg M, Myers R, Negro F, Nemecek V, Örmeci N, Parkes J, Peltekian K, Ramji A, Razavi H, Reis N, Mullhaupt B, Mendes Correa M, Mauss S, Kaita K, Kautz A, Kaymakoglu S, Krajden M, Krarup H, Laleman W, Lavanchy D, Lázaro P, Marotta P, Roberts S, Rosenberg W, Vogel W, Waked I, Wedemeyer H, Weis N, Wiegand J, Yosry A, Zekry A, Van Damme P, Aleman S, Vandijck D, Van Vlierberghe H, van Thiel I, Sarmento-Castro R, Sarrazin C, Semela D, Shiha G, Sievert W, Stärkel P, Stauber R, Thompson A, Urbanek P, Hindman S, Idilman R, Bruggmann P, Bilodeau M, Blasco A, Buti M, Calinas F, Calleja J, Cheinquer H, Christensen P, Clausen M, Coelho H, Bihl F, Balık I, Akarca U, Berg T, Øvrehus A, Moreno C, Brandão Mello C, Roudot-Thoraval F, Marinho R, Sherman M, Ryder S, Sperl J, Cornberg M, Cramp M, García-Samaniego J, Gerstoft J, Giria J, Gonçales F, Gower E, Gschwantler M, Guimarães Pessôa M, Hézode C, Hofer H, Frankova S, Ferreira P, Ferraz M, Dore G, Doss W, Duberg A, El-Sayed M, Ergör G, Esmat G, Estes C, Falconer K, Félix J, Husa P. Historical epidemiology of hepatitis C virus (HCV) in selected countries. J Viral Hepat 2014; 21 Suppl 1:5-33.
01.05.2014Historical epidemiology of hepatitis C virus (HCV) in selected countries
01.05.2014J Viral Hepat 2014; 21 Suppl 1:5-33
Kåberg M, Myers R P, Negro F, Nemecek V, Örmeci N, Parkes J, Peltekian K M, Ramji A, Razavi H, Reis N, Mullhaupt B, Mendes Correa M C, Mauss S, Kaita K D E, Kautz A, Kaymakoglu S, Krajden M, Krarup H, Laleman W, Lavanchy D, Lázaro P, Marotta P, Roberts S K, Rosenberg W M, Vogel W, Waked I, Wedemeyer H, Weis N, Wiegand J, Yosry A, Zekry A, Van Damme P, Aleman S, Vandijck D, Van Vlierberghe H, van Thiel I, Sarmento-Castro R, Sarrazin C, Semela David, Shiha G E, Sievert W, Stärkel P, Stauber R E, Thompson A J, Urbanek P, Hindman S J, Idilman R, Bruggmann P, Bilodeau M, Blasco A J, Buti M, Calinas F, Calleja J L, Cheinquer H, Christensen P B, Clausen M, Coelho H S M, Bihl F, Balık I, Akarca U, Berg T, Øvrehus A L H, Moreno C, Brandão Mello C E, Roudot-Thoraval F, Marinho R T, Sherman M, Ryder S D, Sperl J, Cornberg M, Cramp M E, García-Samaniego J, Gerstoft J, Giria J A, Gonçales F L, Gower E, Gschwantler M, Guimarães Pessôa M, Hézode C, Hofer H, Frankova S, Ferreira P R, Ferraz M L G, Dore G J, Doss W, Duberg A S, El-Sayed M H, Ergör G, Esmat G, Estes C, Falconer K, Félix J, Husa P
Impact of international consensus guidelines on antiviral therapy of chronic hepatitis C patients in Switzerland
Overbeck K, Rickenbach M, Cerny A, Moradpur D, Heim M, Malinverni R, Borovicka J, Helbling B, Mullhaupt B, Dufour J, Negro F. Impact of international consensus guidelines on antiviral therapy of chronic hepatitis C patients in Switzerland. Swiss Med Wkly 2010
03.02.2010Impact of international consensus guidelines on antiviral therapy of chronic hepatitis C patients in Switzerland
03.02.2010Swiss Med Wkly 2010
Overbeck K, Rickenbach M, Cerny A, Moradpur D, Heim M, Malinverni R, Borovicka Jan, Helbling B, Mullhaupt B, Dufour J F, Negro F
Host- rather than virus-related factors reduce health-related quality of life in hepatitis C virus infection
Helbling B, Mullhaupt B, Renner E, Rickenbach M, Bucher S, Negro F, Cerny A, Heim M, Borovicka J, Dufour J, Malinverni R, Gonvers J, Overbeck K, Swiss Hepatitis C Cohort Study. Host- rather than virus-related factors reduce health-related quality of life in hepatitis C virus infection. Gut 2008; 57:1597-603.
01.11.2008Host- rather than virus-related factors reduce health-related quality of life in hepatitis C virus infection
01.11.2008Gut 2008; 57:1597-603
Helbling B, Mullhaupt B, Renner E L, Rickenbach M, Bucher S, Negro F, Cerny A, Heim M, Borovicka Jan, Dufour J-F, Malinverni R, Gonvers J-J, Overbeck K, Swiss Hepatitis C Cohort Study
13C-methacetin breath test as a quantitative liver function test in patients with chronic hepatitis C infection: continuous automatic molecular correlation spectroscopy compared to isotopic ratio mass spectrometry
Goetze O, Selzner N, Fruehauf H, Fried M, Gerlach T, Mullhaupt B. 13C-methacetin breath test as a quantitative liver function test in patients with chronic hepatitis C infection: continuous automatic molecular correlation spectroscopy compared to isotopic ratio mass spectrometry. Alimentary pharmacology & therapeutics 2007; 26:305-11.
15.07.200713C-methacetin breath test as a quantitative liver function test in patients with chronic hepatitis C infection: continuous automatic molecular correlation spectroscopy compared to isotopic ratio mass spectrometry
15.07.2007Alimentary pharmacology & therapeutics 2007; 26:305-11
Goetze O, Selzner N, Fruehauf H, Fried M, Gerlach Tilman, Mullhaupt B
Comparison of two PEG-interferon alpha-2b doses (1.0 or 1.5 microg/kg) combined with ribavirin in interferon-naïve patients with chronic hepatitis C and up to moderate fibrosis
Meyer-Wyss B, Renner E, Arn M, Meyenberger C, Borovicka J, Rossi L, Criblez D, Oneta C, Gonvers J, Rammert C, Mullhaupt B, Helbling B, Egger H, Rich P, Swiss Association for the Study of the Liver (SASL). Comparison of two PEG-interferon alpha-2b doses (1.0 or 1.5 microg/kg) combined with ribavirin in interferon-naïve patients with chronic hepatitis C and up to moderate fibrosis. Journal of viral hepatitis 2006; 13:457-65.
01.07.2006Comparison of two PEG-interferon alpha-2b doses (1.0 or 1.5 microg/kg) combined with ribavirin in interferon-naïve patients with chronic hepatitis C and up to moderate fibrosis
01.07.2006Journal of viral hepatitis 2006; 13:457-65
Meyer-Wyss B, Renner E L, Arn M, Meyenberger Christa, Borovicka Jan, Rossi L, Criblez D, Oneta C, Gonvers J-J, Rammert C, Mullhaupt B, Helbling B, Egger Hp, Rich P, Swiss Association for the Study of the Liver (SASL)
[Acute fatty liver in pregnancy: clinical and histopathological course. Case report]
Wildi S, Reich J, Flury R, Lauper U, Risti B, Mullhaupt B, Meyenberger C. [Acute fatty liver in pregnancy: clinical and histopathological course. Case report]. Praxis 2002; 91:267-73.
13.02.2002[Acute fatty liver in pregnancy: clinical and histopathological course. Case report]
13.02.2002Praxis 2002; 91:267-73
Wildi S M, Reich J, Flury R, Lauper U, Risti B, Mullhaupt B, Meyenberger Christa
Relationship between APC genotype, polyp distribution, and oral sulindac treatment in the colon and rectum of patients with familial adenomatous polyposis
Guldenschuh I, Spigelman A, Hoppeler T, Fried M, Meyenberger C, Roth J, Seelentag W, Flury R, Zala G, Dobbie Z, Mullhaupt B, Ammann R, Muller A, Hürlimann R, Scott R. Relationship between APC genotype, polyp distribution, and oral sulindac treatment in the colon and rectum of patients with familial adenomatous polyposis. Diseases of the colon and rectum 2001; 44:1090-7; discussion 1097-9.
01.08.2001Relationship between APC genotype, polyp distribution, and oral sulindac treatment in the colon and rectum of patients with familial adenomatous polyposis
01.08.2001Diseases of the colon and rectum 2001; 44:1090-7; discussion 1097-9
Guldenschuh I, Spigelman A D, Hoppeler T, Fried M, Meyenberger Christa, Roth J, Seelentag W, Flury R, Zala G F, Dobbie Z, Mullhaupt B, Ammann R, Muller A, Hürlimann R, Scott R J
Lymphocytic colitis: clinical presentation and long term course
Mullhaupt B, Gueller U, Anabitarte M, Güller R, Fried M. Lymphocytic colitis: clinical presentation and long term course. Gut 1998; 43:629-33.
01.11.1998Lymphocytic colitis: clinical presentation and long term course
01.11.1998Gut 1998; 43:629-33
Mullhaupt B, Gueller Ulrich, Anabitarte M, Güller R, Fried M